Return to top of page

FDA Early Alzheimer’s Disease Comment Letter

May 17, 2018   |   Ryne Carney   |   Alzheimer's Disease, FDA & Regulatory Policy

In February 2018, the FDA issued early guidance on clinical trials for early Alzheimer’s disease. The document lays out the FDA’s thinking on how to meaningfully include patients in clinical trials at the earliest stages of the disease. The attached document is a sign-on comment letter circulated by ACT-AD in response to the draft guidance.

Read the FDA Draft Guidance Document Here

File Attachments

Candid Seal of Platinum Transparency 2022

The Alliance for Aging Research is a proud recipient of Candid’s Platinum Seal of Transparency.

Charity Navigator logo

The Alliance for Aging Research is proud to be rated a 4-star charity by Charity Navigator.

Living Longer and Loving It

Sign up for our monthly e-mail newsletter for the latest information on
scientific research on aging and health.